Glenmark Pharmaceuticals Ltd has received tentative approval by the United States Food and Drug Administration (USFDA) for Nentenab Capsules, 100 mg and 150 mg, the generic version of Ofev@1 Capsules, 100 mg and 150 mg, of Beohringer Ingelheim Pharmaceuticals, Inc.
According to IQVIA sales data for the 10 month period ending April 2021, the Ofev@1 Capsules, 100 mg and 150 mg market achieved annual sales of approximately $1.6 billion.
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…